Caliway Biopharmaceuticals Co Ltd 6919
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1,706.72
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Caliway Biopharmaceuticals Co Ltd is specialized in the development of new drugs for medical aesthetic and inflammatory diseases. Its pipeline candidate is, CBL-514, CBA-539, and CBO-012.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 41
- Website
- https://www.caliway.com.tw
Comparables
Valuation
|
Metric
|
6919
|
6838
|
06891
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 25.01 | 5.67 | 3.19 |
Price/Sales | 1,706.72 | 42.92 | 5,531.71 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
6919
|
6838
|
06891
|
|---|---|---|---|
Quick Ratio | 41.62 | 6.43 | 16.22 |
Current Ratio | 41.91 | 6.67 | 16.50 |
Interest Coverage | −1,565.95 | −67.16 | −111.98 |
Quick Ratio
6919
6838
06891
Profitability
|
Metric
|
6919
|
6838
|
06891
|
|---|---|---|---|
Return on Assets (Normalized) | −20.22% | −15.94% | −5.13% |
Return on Equity (Normalized) | −20.87% | −23.61% | −5.43% |
Return on Invested Capital (Normalized) | −21.67% | −23.87% | −6.90% |
Return on Assets
6919
6838
06891
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Ptqklpchsz | Lpv | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Bbhqwrx | Srrpmsp | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Pzgvyttr | Nqlbw | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Njtlydhfk | Kpkgh | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Jzrbbzs | Ckdr | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Zvtmjxtqr | Rspt | $28.0 Bil | |||
| Moderna Inc
MRNA
| Ftlnsbsps | Lscnd | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Gkrhdbqt | Zpcq | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Lfcpwhfm | Wzqwfnv | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Qzckxklg | Mgnqvb | $12.6 Bil |
United States